These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27013142)

  • 1. High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients.
    Vanhove T; Vermeulen T; Annaert P; Lerut E; Kuypers DRJ
    Am J Transplant; 2016 Oct; 16(10):2954-2963. PubMed ID: 27013142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of tacrolimus intra-patient variability on kidney transplant outcomes according to pre-transplant immunological risk.
    Kim EJ; Kim SJ; Huh KH; Kim BS; Kim MS; Kim SI; Kim YS; Lee J
    Sci Rep; 2021 Jun; 11(1):12114. PubMed ID: 34108576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late intra-patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study Report.
    Süsal C; Döhler B
    Am J Transplant; 2019 Oct; 19(10):2805-2813. PubMed ID: 30859672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal Allograft Histology at 10 Years After Transplantation in the Tacrolimus Era: Evidence of Pervasive Chronic Injury.
    Stegall MD; Cornell LD; Park WD; Smith BH; Cosio FG
    Am J Transplant; 2018 Jan; 18(1):180-188. PubMed ID: 28710896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.
    Gatault P; Kamar N; Büchler M; Colosio C; Bertrand D; Durrbach A; Albano L; Rivalan J; Le Meur Y; Essig M; Bouvier N; Legendre C; Moulin B; Heng AE; Weestel PF; Sayegh J; Charpentier B; Rostaing L; Thervet E; Lebranchu Y
    Am J Transplant; 2017 May; 17(5):1370-1379. PubMed ID: 27862923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
    Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
    Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values.
    Leino AD; King EC; Jiang W; Vinks AA; Klawitter J; Christians U; Woodle ES; Alloway RR; Rohan JM
    Am J Transplant; 2019 May; 19(5):1410-1420. PubMed ID: 30506623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients.
    Dugast E; Soulillou JP; Foucher Y; Papuchon E; Guerif P; Paul C; Riochet D; Chesneau M; Cesbron A; Renaudin K; Dantal J; Giral M; Brouard S
    Am J Transplant; 2016 Nov; 16(11):3255-3261. PubMed ID: 27367750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
    Qazi Y; Shaffer D; Kaplan B; Kim DY; Luan FL; Peddi VR; Shihab F; Tomlanovich S; Yilmaz S; McCague K; Patel D; Mulgaonkar S
    Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus intrapatient variability in BK virus nephropathy and chronic calcineurin toxicity in kidney transplantation.
    Turgut D; Sayin B; Soy EA; Topcu Dİ; Ozdemir BH; Haberal M
    Saudi J Kidney Dis Transpl; 2021; 32(2):348-354. PubMed ID: 35017328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
    Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
    Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.
    Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L
    Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation.
    Davis S; Gralla J; Klem P; Tong S; Wedermyer G; Freed B; Wiseman A; Cooper JE
    Am J Transplant; 2018 Apr; 18(4):907-915. PubMed ID: 28925597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation.
    Wissing KM; Abramowicz D; Weekers L; Budde K; Rath T; Witzke O; Broeders N; Kianda M; Kuypers DRJ
    Am J Transplant; 2018 Jul; 18(7):1726-1734. PubMed ID: 29337426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
    Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
    Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kidney allograft failure in the steroid-free immunosuppression era: A matched case-control study.
    Alkadi MM; Kim J; Aull MJ; Schwartz JE; Lee JR; Watkins A; Lee JB; Dadhania DM; Seshan SV; Serur D; Kapur S; Suthanthiran M; Hartono C; Muthukumar T
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28921709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.
    Shuker N; Bouamar R; van Schaik RH; Clahsen-van Groningen MC; Damman J; Baan CC; van de Wetering J; Rowshani AT; Weimar W; van Gelder T; Hesselink DA
    Am J Transplant; 2016 Jul; 16(7):2085-96. PubMed ID: 26714287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients.
    Taber DJ; Chokkalingam A; Su Z; Self S; Miller D; Srinivas T
    Clin Transplant; 2019 Oct; 33(10):e13679. PubMed ID: 31365151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.
    Shihab F; Qazi Y; Mulgaonkar S; McCague K; Patel D; Peddi VR; Shaffer D
    Am J Transplant; 2017 Sep; 17(9):2363-2371. PubMed ID: 28141897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.